Showing results (51-60 of 64) with videos related to
Sort By:
Pageof 7
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 13, 2007
Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled studyPaul D Miller, Arkadi A Chines, Claus Christiansen, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 15, 2010
Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal Japanese women with osteoporosisAkira Itabashi, Kousei Yoh, Arkadi A Chines, et al.Menopause (New York, N.Y.)|June 23, 2009
Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal womenDavid F Archer, JoAnn V Pinkerton, Wulf H Utian, et al.BMC Musculoskeletal Disorders|June 24, 2010
Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosisClaus Christiansen, Charles H Chesnut, Jonathan D Adachi, et al.Calcified Tissue International|September 23, 2000
Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapyS Wallach, S Cohen, D M Reid, et al.Arthritis and Rheumatism|November 11, 1999
Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyS Cohen, R M Levy, M Keller, et al.The New England Journal of Medicine|August 7, 1997
Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosisJ D Adachi, W G Bensen, J Brown, et al.Menopause (New York, N.Y.)|February 11, 2015
A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fractureSantiago Palacios, Stuart L Silverman, Tobie J de Villiers, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 25, 2022
Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney DiseasePaul D Miller, Jonathan D Adachi, Ben-Hur Albergaria, et al.Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|June 16, 2019
Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over groupJ P Bilezikian, C J F Lin, J P Brown, et al.Pageof 7